Panacea Biotec

Panacea Biotec GmbH is an innovation-driven biotechnology group primarily focused on the discovery, development, and commercialization of prescription drugs. The company's facilities have been prequalified by the World Health Organization (WHO), approved by the U.S. Food and Drug Administration (FDA), and comply with current Good Manufacturing Practices (cGMP). Panacea Biotec GmbH is also responsible for the development of a novel tetravalent dengue vaccine and a pneumococcal conjugate vaccine, along with other distinctive drug development projects.